Publications
Detailed Information
Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Na, Ki Young | - |
dc.contributor.author | Kim, Dong Ki | - |
dc.contributor.author | Kim, Sung Gyun | - |
dc.contributor.author | Lee, Young-Ki | - |
dc.contributor.author | Lim, Chun Soo | - |
dc.date.accessioned | 2013-10-02T04:40:19Z | - |
dc.date.available | 2013-10-02T04:40:19Z | - |
dc.date.issued | 2013-09-02 | - |
dc.identifier.citation | Trials Vol.14 No.275, pp. 1-6 | ko_KR |
dc.identifier.issn | 1745-6215 | - |
dc.identifier.uri | https://hdl.handle.net/10371/83495 | - |
dc.identifier.uri | http://www.trialsjournal.com/content/14/1/275 | - |
dc.description | Trial registration : ClinicalTrials.gov number NCT01796418 | ko_KR |
dc.description.abstract | Background : Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Cardiovascular (CV) complications are the most common cause of death among ESRD patients. Beraprost sodium (BPS) is a prostacyclin analog with vasodilatory and antiplatelet effects.
Methods : This is a multicenter prospective, randomized, double-blind, placebo-controlled trial to determine whether treatment with BPS improves arterial stiffness in patients with type 2 diabetic nephropathy. A total of 102 participants with type 2 diabetic nephropathy will be screened, enrolled, and randomly assigned to receive either 80 μg BPS or placebo daily for 12 weeks. The primary outcome is the change in brachial-ankle pulse wave velocity between baseline and after 12 weeks of medication use. The secondary outcomes will include changes in the ankle-brachial index, the urine albumin to creatinine ratio, the estimated glomerular filtration rate, lipid profiles, and blood pressure from baseline to after treatment. Discussion : This clinical trial is the first to investigate the effects of BPS on changes in CV biomarkers, albuminuria, renal function, and lipid profiles in patients with diabetic nephropathy. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central Ltd. | ko_KR |
dc.subject | Beraprost sodium | ko_KR |
dc.subject | Arterial stiffness | ko_KR |
dc.subject | Diabetic nephropathy | ko_KR |
dc.subject | Cardiovascular | ko_KR |
dc.subject | Pulse wave velocity | ko_KR |
dc.title | Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 나기영 | - |
dc.contributor.AlternativeAuthor | 김동기 | - |
dc.contributor.AlternativeAuthor | 김성균 | - |
dc.contributor.AlternativeAuthor | 이영기 | - |
dc.contributor.AlternativeAuthor | 김춘수 | - |
dc.identifier.doi | 10.1186/1745-6215-14-275 | - |
dc.citation.journaltitle | Trials | - |
dc.language.rfc3066 | en | - |
dc.description.version | Peer Reviewed | - |
dc.rights.holder | Ki Young Na et al.; licensee BioMed Central Ltd. | - |
dc.date.updated | 2013-10-01T19:31:22Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.